期刊
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 16, 期 5, 页码 601-604出版社
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2018.0046
关键词
-
类别
资金
- AbbVie
- ACEA
- Adaptimmune
- ARIAD Pharmaceuticals, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Genentech, Inc.
- Guardant
- Loxo Oncology
- Novartis Pharmaceuticals Corporation
- Pfizer Inc.
- Seattle Genetics
- Xcovery
- Amgen Inc.
- Astellas
- Euclises
- Tesaro, Inc.
Molecular testing is recommended for initial diagnosis in patients with non-small cell lung cancer (NSCLC), according to the updated NCCN Guidelines, because targeted therapies are available that can improve patient outcomes. Targeted therapies are currently approved for EGFR mutations, ALK and ROS1 gene rearrangements, and BRAF mutations, with the list of emerging actionable targets growing. The 2018 NCCN Guidelines for NSCLC incorporate new therapies, including the EGFR tyrosine kinase inhibitor osimertinib and the ALK inhibitor alectinib, as first-line preferences.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据